User:Mr. Ibrahem/Brolucizumab

Brolucizumab, sold under the brand names Beovu and Vsiqq, is a medication used to treat wet age-related macular degeneration (AMD). It is given by injection into the eye.

Common side effects include reduced visual acuity, cataracts, conjunctival bleeding, and floaters. Other side effects may include blindness, infection inside the eye, retinal artery occlusion, and retinal detachment. Use in pregnancy may harm the baby. It is a piece of a monoclonal antibody that attaches to and block vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid.

Brolucizumab was approved for medical use in the United States in 2019 and Europe in 2020. In the United Kingdom it costs the NHS about £820 per dose as of 2021. This amount in the United States is about 1,950 USD.